Cytoreductive surgery combined with hyperthermic intrapleural chemotherapy to treat thymoma or thymic carcinoma with pleural dissemination

Yu, Lei; Yun, Jimmy; Ma, Shan; Li, Fēi; Zhang, Yunfeng

doi:10.2147/ott.s41347

Cited by 26 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Tables 1 and 2, total 5 articles were included in the meta-analysis (quantitative synthesis) [5–9] and 22 articles were included in the systematic review (qualitative synthesis). Among the 27 articles for systematic review and meta-analysis, 4 articles were from Japan, [5,6,10,11] 4 articles from China, [7,9,12,13] 4 articles from Italy, [14–17] 4 articles from Netherlands, [18–21] 3 articles from USA, [22–24] 3 articles from Germany, [25–27] 2 articles from Israel, [28,29] 1 from Turkey, [8] 1 from Australia, [30] and 1 from Korea. [31] The earliest was reported in 1995 by Matsuzaki et al from Japan (Matsuzaki, 1995], and the latest, up to May 2016, was from China by Liu et al [13] and from Italy by Ambrogi et al [17] …”

Section: Resultsmentioning

confidence: 99%

Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion

Zhou

Wu²,

Tang³

et al. 2017

Medicine

View full text Add to dashboard Cite

Background:Although hyperthermic intraperitoneal chemotherapy (HIPEC) has been widely used to treat malignant ascites or as a preventive strategy for microscopic carcinomatosis following surgical resection of abdominal tumors, application of hyperthermic intrathoracic chemotherapy (HITHOC) in the treatment of malignant pleural effusion is limited. The objective of the current study was to conduct a systematic review and meta-analysis on the application of HITHOC in the palliative treatment of malignant pleural effusion.Methods:After thorough searching of online databases, total 27 articles were included into qualitative systematic review and 5 of them were used to conduct qualitative meta-analysis.Results:It was found that most of HITHOC was used in combination of cytoreductive surgery (CRS) including pleurectomy/decortication or after surgical resection of primary tumors, which mainly were lung cancer, thymoma or thymic carcinoma, breast cancer, and ovarian cancer. Patients who received HITHOC had significantly longer median survival length compared to the patients without HITHOC (Hedges g = 0.763, P < 0.001). In addition, HITHOC therapy was favored (Hedges g = 0.848, P < 0.001) in terms of median survival length, tumor-free survival rate, with tumor survival rate or Karnofsky performance status (KPS) scale.Conclusion:HITHOC is a safe and effective therapy in controlling pleural effusion and increasing patient's survival rate.

show abstract

Section: Resultsmentioning

confidence: 99%

Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion

Zhou

Wu²,

Tang³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…They rarely metastasize to distant sites; on the contrary, they more often show pleural implantation at diagnosis or during follow-up. Thymoma with pleural spread is also a dificult clinical situation to manage, and the treatment is controversial [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

“…PDT anticancer efect occurs when the photosensitizer captures light energy and transfers that energy to oxygen. The excited oxygen species are responsible for the efect and can directly kill tumor cells, damage the tumor blood supply, or both [10]. Porimer sodium (Photofrin; Axcan Pharma Inc, Birmingham, AL, USA), a irst-generation photosensitizer that is a mixture of porphyrin monomers and oligomers, is used most often.…”

Section: Introductionmentioning

confidence: 99%

Pleural Photodynamic Therapy and Surgery in Thoracic Cancer Patients with Pleural Spread

Chen¹,

Lee²

2017

Photomedicine - Advances in Clinical Practice

View full text Add to dashboard Cite

Pleural spread from non-small cell lung cancer is a diicult situation. The average survival in the situation is about 6-9 months. We investigate the current management of this challenging condition. Although, there is no much evidence found in the literature, we do see the pleural photodynamic therapy giving some promising light in the dark night. However, the patients still require complete neoadjuvant and adjuvant therapies, as well as radical tumor resection. Pleural PDT is one of the multi-modality treatments, which combined can achieve satisfactory oncological results. The long-term survival can be achieved in more than half the patients. However, the side efects of pleural PDT include skin hypersensitivity, trachea and esophageal perforation, and ARDS, which we should keep in mind.

show abstract

“…Extensive surgical resection combined with IPHC is a well-known surgical approach for malignant pleural mesothelioma (7,8), and has been used to treat thymic carcinoma with pleural dissemination (9). Promising results of surgical resection combined with IPHC for lung cancer with pleural dissemination have also been reported (10,11).…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination

Kim

Cho

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: This study aimed to investigate the safety and feasibility of intrapleural perfusion hyperthermic chemotherapy (IPHC) followed by cytoreductive surgery as a part of multimodal strategy for the treatment of advanced lung adenocarcinoma. Methods: Medical records of advanced lung cancer patients with pleural dissemination who underwent surgical treatment between 2003 and 2013 were reviewed retrospectively. Enrolled patients were divided into a surgery group comprising patients who underwent surgery only and an IPHC group, which consisted of patients who underwent surgery combined with IPHC. Results: A total of 33 patients were enrolled in this study. Twenty-three patients underwent IPHC after surgical resection, and 10 patients underwent surgical resection only. The complication rate of the IPHC group was estimated to be 34.8% (8 cases), none of which included postoperative mortality. The complication rate of the surgery group was 40.0% (4 cases), which included one postoperative mortality.The 6-month, 1-year, and 3-year overall survival rates for the IPHC group were 95.7%, 91.3% and 38.6%, respectively, while those of the surgery group were 80.0%, 80.0% and 37.5%. The 6-month, 1-year and 3-year progression-free survival rates for the IPHC group were 87.0%, 47.8% and 24.3%, while those of surgery group were 44.4%, 33.3% and 0.0%, respectively. There were significant differences in overall survival rates between two groups (P=0.045); however, progression-free survival was not different between the two groups. Conclusions: IPHC combined with cytoreductive surgery for advanced lung adenocarcinoma associated with pleural seeding could be performed safely and feasible. It would be part of multimodality therapy for certain category of advanced lung adenocarcinoma. However, the long-term benefits for survival is uncertain.More extensive and precisely designed studies are warranted to further evaluate the effectiveness of IPHC.

show abstract

Cytoreductive surgery combined with hyperthermic intrapleural chemotherapy to treat thymoma or thymic carcinoma with pleural dissemination

Cited by 26 publications

References 17 publications

Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion

Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion

Pleural Photodynamic Therapy and Surgery in Thoracic Cancer Patients with Pleural Spread

Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination

Contact Info

Product

Resources

About